Pregabalin Capsule
Product Images NDC 58118-1462

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 58118-1462). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 25mg Capsule 30ct Blister Card (Prega 25mg 90s A)

Label for Pregabalin 25 mg Capsules from Clinical Solutions Wholesale, LLC. The label includes the product's NDC 58118-1462-8, a quantity of 30 capsules, manufacturing details by Ascend Laboratories, LLC in Parsippany, NJ, and batch and serial numbers. It also features a barcode and a QR code.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for estimating creatinine clearance (CLCr) based on age in years, body weight in kilograms, serum creatinine in mg/dL, and a correction factor for female patients. This is a clinical calculation relevant to drug dosing or kidney function assessment.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

A bar chart depicting responder rates (%) on the vertical axis for three groups with sample sizes indicated on the horizontal axis: Placebo (93 subjects) with 22.6%, 2.5 mg/kg/day dose (103 subjects) with 29.1%, and 10 mg/kg/day dose (96 subjects) with 40.6%.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

Bar graph depicting responder rates in percentage for Pregabalin at various dosages compared to placebo in two studies labeled E1 and E3. Study E1 shows rates for placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day doses administered BID. Study E3 shows rates for placebo, 600 mg/day BID, and 600 mg/day TID doses. The graph includes the number of subjects (N) per group and indicates statistically significant results versus placebo with an asterisk.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as the median percentage change from baseline versus dose (mg/day) for Pregabalin. It compares different dosing schedules across three studies (E1 BID, E2 TID, E3 BID, E3 TID). The graph includes statistical significance markers (p-values) for placebo and various dose levels, illustrating dose-dependent seizure reduction.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the percent improvement in pain from baseline versus the percent of patients improved. The graph compares four lines representing different dosages of Pregabalin capsules (25 mg, 100 mg, 200 mg taken three times a day) and a placebo group, showing trends in patient improvement across varying levels of pain relief.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph depicting the percent of subjects improved versus percent improvement from baseline to Week 12 BOCF comparing Pregabalin and Placebo groups. The x-axis ranges from greater than 0 to 100 percent improvement, and the y-axis shows the percent of subjects improved up to 100 percent.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent improved from baseline to week 16 using the Brief Pain Inventory (BPI) for Pregabalin versus placebo. The x-axis represents the percent improved, and the y-axis shows the percent of subjects improved. Two lines are shown: one solid for Pregabalin and one dashed for placebo, illustrating higher improvement with Pregabalin over placebo across the measured range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. It compares two groups: Pregabalin 100 mg three times a day and placebo, displaying higher improvement percentages for the Pregabalin group across the pain improvement scale.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The graph depicts descending improvement trends across varying dosages over the improvement scale.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph tracks improvements across a range from 0 to 100 percent pain improvement.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo. The vertical axis represents the percent of patients improved from 0 to 100%, and the horizontal axis shows percent improvement in pain from baseline ranging from greater than 0 to 100%.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The chart shows the percentage of subjects without LTR on the vertical axis and days on the horizontal axis, with distinct curves for Pregabalin and placebo.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of Pregabalin shown with its molecular components including CO2H (carboxyl group) and NH2 (amino group). The diagram illustrates the arrangement of carbon, hydrogen, and functional groups characteristic of Pregabalin's molecular formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.